<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217109</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A01592-55</org_study_id>
    <nct_id>NCT04217109</nct_id>
  </id_info>
  <brief_title>Transcutaneous Breast Cancer Diagnosis by Canine Odorology</brief_title>
  <acronym>KDOG1</acronym>
  <official_title>KDOG1 :Transcutaneous Breast Cancer Diagnosis by Canine Odorology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient with an indication of interventional percutaneous procedure for characterization of a
      breast lesion, palpable or not, classified as category 4 or 5, according to the Breast
      Imaging (BI) Report and Data System of the American College of Radiology (RADS)
      classification detected at mammography and/or breast ultrasound examination.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the sensitivity and specificity of canine odorology in women with breast lesion</measure>
    <time_frame>26 months</time_frame>
    <description>The sensitivity and specificity of canine odorology in women with undeterminate breast lesion classified American College of Radiology (ACR) 4 or 5 (typically malignant) will be compared to the anatomopathological results of breast percutaneous sampling (biopsy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity (markings on patients affected) and specificity (no-markings on patients not affected)</measure>
    <time_frame>38 months</time_frame>
    <description>Number of markings among compresses of patients affected and number of no-markings among compresses of patients not affected. The gold standard is the pathological examination of the operative specimen or the status of the patient at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV) and negative predictive value (NPV) of canine odorology</measure>
    <time_frame>38 months</time_frame>
    <description>Number of compresses of patient affected on number of markings (PPV) and number of compresses of patient non affected on number of no-markings (NPV) will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance during the study</measure>
    <time_frame>26 months</time_frame>
    <description>The rate of return of compresses after delivery of a kit will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between canine odorology and mammography</measure>
    <time_frame>38 months</time_frame>
    <description>Comparison test of sensitivity and specificity values between canine odorology and mammography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of each dog</measure>
    <time_frame>26 months</time_frame>
    <description>Sensitivity and specificity of canine odorology for each dog will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability between dogs</measure>
    <time_frame>26 months</time_frame>
    <description>A Cohen's kappa test will be used to explore the variability between trained dogs and dog breeds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of canine odorology if the test is based on 2 dogs</measure>
    <time_frame>24 months</time_frame>
    <description>The results of the 2 dogs will be used to compare the performances</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's satisfaction</measure>
    <time_frame>26 months</time_frame>
    <description>A questionnaire will be completed by the patients to measure their satisfaction and indicate their level of agreement. A score from 0 (no anxiety) to 5 (very anxious) on a scale will be completed to assess anxiety, a score from 0 (very difficult) to 5 (very easy) will be used to ensure that the compress is easy to use.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Odour sampling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Odour collection will be obtained by positioning a compress on the breast concerned during the night preceding the day of samplings. The compress, once removed, will be placed in specific envelope for the study. Envelope will be given to the investigating centre during the appointment of percutaneous samples and then sent to the sponsor center (Institute Curie Paris).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Odour sampling</intervention_name>
    <description>Upon receipt of the samples at the Institute Curie-Paris, the compresses will be packed in jars and then transmitted to the dog center and analyzed by the study dogs.
Positive marking is characterized by a sitting position of the dog in front of the sample.</description>
    <arm_group_label>Odour sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women 18 years and older, with one or more ipsilateral mammary lesion(s), palpable or
             not, detected at mammography and/or ultrasound and with at least one lesion classified
             as BI-RADS® category 4 or 5 with an indication of percutaneous sampling (cytology,
             microbiopsies, macro-biopsies) ;

          2. Benefit from the national social security ;

          3. Signature of the informed consent of the study ;

          4. There is no contraindication for the person to simultaneously participate to another
             research program and there is no exclusion period planned after the study.

        Exclusion Criteria:

          1. Patient with bilateral breast lesions classified as BI-RADS® category 4 or 5;

          2. Patient with breast implant(s);

          3. Patient with a personal history of breast surgery for benign lesion(s) of the
             concerned breast operated less than 4 weeks before the date of inclusion in this
             study;

          4. Patient with a personal history of cancer (in situ or invasive) less than 5 years
             before inclusion whatever the anatomical site including cutaneous basal cell
             carcinoma;

          5. Patient with a personal history of punctures and/or percutaneous breast biopsies of
             the concerned breast less than 4 weeks before inclusion;

          6. Patient with a breast skin ulceration;

          7. Patient under insulin (risk of sudation that may impair compress sample);

          8. Concomitant antibiotics or corticoids taken one week before inclusion in the study;

          9. Patient with a current viral infection (fever);

         10. Persons under guardianship or deprived of liberty;

         11. Impossibility to submit to the medical monitoring expected by the study for
             geographical or severe psychological reasons.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANNE TARDIVON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ISABELLE FROMANTIN, PhD, IDE</last_name>
    <phone>+33 1 44324428</phone>
    <email>drci.promotion@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AURELIE THULEAU, PROJECT MANAGER</last_name>
    <phone>+33 1 44324228</phone>
    <email>aurelie.thuleau@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <zip>44</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FRANCOIS DRAVET, MD</last_name>
      <email>Francois.dravet@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>FRANCOIS DRAVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'imagerie 114</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CATHERINE ALA EDDINE, MD</last_name>
      <email>calaeddine@free.fr</email>
    </contact>
    <investigator>
      <last_name>CATHERINE ALA EDDINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint- Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-rose El BEJJANI, MD</last_name>
      <email>mrelbejjani@hpsj.fr</email>
    </contact>
    <investigator>
      <last_name>MARIE-ROSE EL BEJJANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANNE TARDIVON, MD</last_name>
      <email>anne.tardivon@curie.fr</email>
    </contact>
    <investigator>
      <last_name>ANNE TARDIVON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ADRIANA LANGER, MD</last_name>
      <email>adriana.langer@curie.fr</email>
    </contact>
    <investigator>
      <last_name>ADRIANA LANGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>EDOUARD PONCELET, MD</last_name>
      <email>poncelet.edouard@gmail.com</email>
    </contact>
    <investigator>
      <last_name>EDOUARD PONCELET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Dog Detection</keyword>
  <keyword>Volatile organic Compounds</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

